Michael Brennan, DO
Endocrinology, Diabetes & Metabolism · Saint Clair Shores, MINPI 1689889388
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $375,921 of the $433,111 with a category attached, or 86.8%. Novo Nordisk accounts for 71.5% of it on its own, with 18 other manufacturers making up the rest. Among endocrinology, diabetes & metabolism clinicians in MI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 415 payments — averaging $1043.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$310K
- Bayer$89K
- Boehringer Ingelheim$13K
- Lilly USA, LLC$12K
- Insulet Corporation$3K
- Valeritas, Inc.$2K
- plus $4K from 13 others
What the payments were for
- Consulting fees$4,4991%
- Speaking & faculty fees$375,92187%
- Travel & lodging$41,78110%
- Food & beverage$10,8473%
- Education$650%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 229 | $309,657 |
| Bayer | 71 | $89,126 |
| Boehringer Ingelheim | 24 | $13,248 |
| Lilly USA, LLC | 17 | $12,089 |
| Insulet Corporation | 1 | $2,534 |
| Valeritas, Inc. | 6 | $2,493 |
| Dexcom, Inc. | 5 | $1,591 |
| Abbott | 46 | $956 |
| Tandem Diabetes Care, Inc. | 3 | $769 |
| BD | 1 | $250 |
| Nevro Corp. | 4 | $137 |
| AstraZeneca | 1 | $127 |
| Saluda Medical Americas, Inc. | 1 | $35 |
| Averitas Pharma Inc. | 1 | $22 |
| Si-bone, Inc. | 1 | $18 |
| AbbVie | 1 | $17 |
| Ascensia Diabetes Care US Inc. | 1 | $16 |
| Boston Scientific | 1 | $15 |
| BETA Bionics, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- RYBELSUS$134,840
- Kerendia$88,348
- Wegovy$73,084
- Ozempic$63,768
- JARDIANCE$23,453
- Omnipod$2,534
- V-GO$2,400
- DEXCOM G6 CGM SYSTEM$1,498
- t-slim insulin pump$709
- BD Nano 2nd Gen Pen Needle$250
- FreeStyle Libre 2$248
- MOUNJARO$125
- Tresiba$108
- Victoza$108
- Xultophy 100/3.6$108
How this compares
$433,111 in reported general payments places this provider in the 95th percentile of 219 endocrinology, diabetes & metabolism providers in Michigan.
See all endocrinology, diabetes & metabolism providers in Michigan →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 19 | $22,402 |
| OzempicSemaglutide | 18 | $20,186 |
| FarxigaDapagliflozin Propanediol | 11 | $12,276 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $13,248 | $22,40219 claims |
| Novo NordiskOzempic | $309,657 | $20,18618 claims |
| AstraZenecaFarxiga | $127 | $12,27611 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 219 endocrinology, diabetes & metabolism providers in Michigan.
Other endocrinology, diabetes & metabolism in Saint Clair Shores
- Lowell SchmeltzFarmington Hills$1.3M
- George GrunbergerBloomfield Hills$931K
- Gary EdelsonFarmington Hills$503K
- Jamal HammoudFlint$386K
- Abdulsalam Al KassabRochester Hills$351K
- Richard AuchusAnn Arbor$250K
- Eric LangerSterling Heights$213K
- Ashish VermaShelby Twp$179K
- Kara HoisingtonLansing$178K
- Henry BoneDetroit$120K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.